MedTech Company ReEmerge Raises $37M in Series A Funding

The round also saw participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.

The company plans to use the funding to expand its operations and development efforts.

What is ReEmerge?

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT), a technology designed to address cognitive impairment following brain injury.

CNRT targets neural networks in the central thalamus, a brain region involved in attention, arousal, and executive function. The approach is designed to stimulate underactive but viable neural circuits rather than bypass damaged pathways.

Read More:Virginia-Based Radian Forge Raises $2.5M in Seed Funding

The technology aims to support the recovery of cognitive function by restoring activity across existing neural networks.

How Much Funding Has ReEmerge Raised?

ReEmerge has raised $37 million in its latest Series A funding round.

The round was co-led by U.S. Venture Partners (USVP) and Santé, with participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.

No previous funding details were provided.

Who Invested in ReEmerge’s Series A Round?

The Series A was co-led by:

• U.S. Venture Partners (USVP)
• Santé

Participating investors included:

• Oxford Science Enterprises
• 415 Capital
• IAG Capital Partners
• The Vertical Group
• Dendrion Ventures

Why the Funding Matters

ReEmerge plans to use the new funding to expand operations and development efforts around CNRT.

The technology grew out of research led by Nicholas Schiff, M.D., Professor of Neuroscience at Weill Cornell Medicine, along with researchers at Stanford University and the University of Utah.

The foundational intellectual property was licensed exclusively to ReEmerge through the Center for Technology Licensing at Weill Cornell.

Who founded ReEmerge?

The provided information does not name ReEmerge's founders.

The company is headquartered in New York City and operates under an exclusive licensing agreement with Cornell University.

Market and Business Growth

ReEmerge's technology is based on decades of research into brain electrical stimulation following traumatic brain injury (TBI), including research published in Nature Medicine.

The company plans to conduct a prospective, single-arm, multicenter study (NCT07730099) involving up to 40 patients with chronic moderate-to-severe TBI.

The study will evaluate CNRT and explore its potential effects on cognitive and functional outcomes.

An estimated 27 million people worldwide experience traumatic brain injury each year, with many experiencing persistent cognitive impairment.

What Happens Next?

ReEmerge will advance the clinical development of CNRT and conduct its planned multicenter study in patients with chronic moderate-to-severe TBI.

The company will continue developing its approach to restoring function across underactive but viable neural networks affected by brain injury.

Read More:Construction-Based Scaffold Raises $15M in Seed Funding